Tablets, Lozenges, Or Pills Patents (Class 424/464)
  • Patent number: 9326982
    Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: May 3, 2016
    Assignee: Pemix Ireland Pain Limited
    Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
  • Patent number: 9295642
    Abstract: An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: March 29, 2016
    Assignee: Tris Pharma, Inc.
    Inventors: Yu-Hsing Tu, Ashok Perumal, Kalyan Kathala
  • Patent number: 9289386
    Abstract: The present invention provides a film-form base having one or more sugars or sugar alcohols dispersed as fine particles therein, and also provides a film-form preparation containing the base and a drug. The base is produced by dispersing, in an organic solvent having a solubility parameter of 9.7 or higher, an edible polymer soluble in water and the organic solvent, and particles of one or two or more compounds selected from the group consisting of mono- to hexasaccharide sugars and sugar alcohols thereof which have an average particle size of 0.1 ?m to 60 ?m and are insoluble in an organic solvent. The present invention can therefore provide oral film-form base and preparation which have a rapid dissolution profile in the mouth and sufficient film strength, and provide a reduced sticky sensation attributed to the water-soluble polymer in the mouth and an improved feel when handled with the fingers.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: March 22, 2016
    Assignee: NITTO DENKO CORPORATION
    Inventors: Daisuke Asari, Mitsuhiko Hori, Keiko Ogawa
  • Patent number: 9278063
    Abstract: The purpose of the invention is to provide a press-coated orally-disintegrating tablet having a powder/granular material with poor formability in its inner core, which has an excellent disintegrability and a suitable hardness as a whole tablet. Furthermore, the invention is a press-coated orally-disintegrating tablet with an outer layer surrounding an inner core wherein the inner core has a thickness in the range of 30 to 80% per that of the whole tablet, and the outer layer comprises (a) microcrystalline cellulose, (b) a sugar or a sugar alcohol, and (c) one or more particular ingredients selected from the group consisting of crospovidone, starches, low-substituted hydroxypropylcellulose and carmellose.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: March 8, 2016
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Yuki Ikeda, Yasushi Ochiai
  • Patent number: 9271951
    Abstract: A pharmaceutical composition comprising thyroxine, acacia, and an antioxidant selected from propyl gallate, butylated hydroxyanisol, and butylated hydroxytoluene is disclosed. The pharmaceutical composition has an improved shelf life. In one embodiment, the composition additionally comprises sucrose, microcrystalline cellulose, and mannitol. The pharmaceutical composition may be used for treating thyroid disorders by orally administering the composition to a patient in need thereof.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: March 1, 2016
    Assignee: Mylan Inc.
    Inventors: John Kirsch, Ramakrishna Nallamothu, Baris E. Polat
  • Patent number: 9265760
    Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: February 23, 2016
    Assignee: Pemix Ireland Pain Limited
    Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
  • Patent number: 9259454
    Abstract: The present invention provides a solid composition comprising the following ingredients (A) and (B): (A) wheat albumin, and (B) a C6 to C12 sugar alcohol, wherein a content mass ratio of the ingredient (B) to the ingredient (A), (B)/(A), is 0.2 or higher.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: February 16, 2016
    Assignee: KAO CORPORATION
    Inventors: Aiko Shudo, Shin Koike, Nobuteru Ishizuka
  • Patent number: 9254261
    Abstract: A quick dissolving pharmaceutical formulation is disclosed. In one embodiment, the formulation includes at least the following components: (1) from about 35 to about 50 weight percent amoxicillin or a pharmaceutically acceptable salt thereof; (2) from about 2.0 to about 12 weight percent clavulanic acid or a pharmaceutically acceptable salt thereof; (3) from about 30 to about 40 weight percent mannitol; (4) from about 2 to about 7 weight percent crospovidone; (5) from about 0.5 to about 2.0 weight percent colloidal silicon dioxide; and (6) from about 2.0 to about 5.0 weight percent sodium stearyl fumarate. A method for making a quick dissolving pharmaceutical tablet is also disclosed.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: February 9, 2016
    Assignee: Sandoz AG
    Inventors: Rok Staric, Marko Oblak, Tanja Rozman Peterka, Veronika Debevec
  • Patent number: 9248102
    Abstract: The tablet containing (1) 5-hydroxy-1H-imidazole-4-carboxamide or a salt thereof, or a hydrate thereof, and (2) silicon dioxide has a high content of 5-hydroxy -1H-imidazole-4-carboxamide or a salt thereof, or a hydrate thereof and an easily takable size as a tablet, and shows superior dissolution property.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: February 2, 2016
    Assignee: FUJIFILM Corporation
    Inventor: Yasuomi Yamasaki
  • Patent number: 9241910
    Abstract: The present invention provides an orally-disintegrating solid preparation such as a tablet produced by tabletting fine granules showing controlled release of a pharmaceutically active ingredient and an additive, and the like, and the orally-disintegrating solid preparation containing fine granules coated with a coating layer containing a polymer affording a casting film having an elongation at break of about 100-about 700%. With the preparation, breakage of fine granules during tabletting can be suppressed in the production of an orally-disintegrating solid preparation containing fine granules showing controlled release of a pharmaceutically active ingredient.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: January 26, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takashi Kurasawa, Yasuko Watanabe, Yoshihiro Omachi
  • Patent number: 9241945
    Abstract: Provided is a dry coated tablet showing high stability of the active ingredient (proton pump inhibitor, acetylsalicylic acid), which stably and rapidly expresses the pharmacological effect of the active ingredient after administration. A dry coated tablet having an inner core and an outer layer, wherein the inner core is an enteric-coated tablet containing acetylsalicylic acid, and the outer layer contains enteric micro granules containing a proton pump inhibitor.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: January 26, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tetsuya Kawano, Yasushi Mima, Yumiko Ishii
  • Patent number: 9238007
    Abstract: The invention relates to a method for producing a medicament containing tadalafil. In said method, tadalafil is mixed with suitable adjuvants and is heated to a temperature of about 100° C. to about 200° C., preferably about 150° C. to about 200° C., especially about 200° C.
    Type: Grant
    Filed: June 23, 2008
    Date of Patent: January 19, 2016
    Assignee: RATIOPHARM GMBH
    Inventors: Rainer Alles, Julia Schulze Nahrup, Katrin Rimkus
  • Patent number: 9238004
    Abstract: The present invention provides a film-form base having one or more sugars or sugar alcohols dispersed as fine particles therein, and also provides a film-form preparation containing the base and a drug. The base is produced by dispersing, in an organic solvent having a solubility parameter of 9.7 or higher, an edible polymer soluble in water and the organic solvent, and particles of one or two or more compounds selected from the group consisting of mono- to hexasaccharide sugars and sugar alcohols thereof which have an average particle size of 0.1 ?m to 60 ?m and are insoluble in an organic solvent. The present invention can therefore provide oral film-form base and preparation which have a rapid dissolution profile in the mouth and sufficient film strength, and provide a reduced sticky sensation attributed to the water-soluble polymer in the mouth and an improved feel when handled with the fingers.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: January 19, 2016
    Assignee: NITTO DENKO CORPORATION
    Inventors: Daisuke Asari, Mitsuhiko Hori, Keiko Ogawa
  • Patent number: 9220704
    Abstract: The present invention relates to a hard capsule composite formulation comprising a capsule having a hemispherical closure at each end and an interior space; and one or more tablets encapsulated in the capsule, wherein the tablet or the tablets as a whole have a shape conforming to the internal space of the capsule. The hard capsule composite formulation can efficiently charge pharmaceutical compositions inside the limited interior space of the capsule, and hence, it allows packing a high-dose of pharmaceutical composition in a relatively small-sized capsule, which increases productivity and patient compliance. Also, the composite formulation exhibits good dissolution rate because pharmaceutically active ingredients contained in the capsule are separated from one another, and thus, the ingredients are less affected by the dissolution rate of one another, allowing good storage stability which can optimize the therapeutic effects.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: December 29, 2015
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Kyeong Soo Kim, Ki Young Jang, Seung Jae Park, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
  • Patent number: 9211263
    Abstract: Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.
    Type: Grant
    Filed: January 5, 2013
    Date of Patent: December 15, 2015
    Assignee: Elcelyx Therapeutics, Inc.
    Inventors: Alain D. Baron, Mark S. Fineman, Nigel R. A. Beeley
  • Patent number: 9211261
    Abstract: High loading immediate release dosage forms containing at least 30 wt % of a solid drug dispersion, at least 5 wt % of a disintegrant and a porosigen are disclosed that exhibit excellent strength and aqueous solubility.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: December 15, 2015
    Assignee: Bend Research, Inc.
    Inventors: Leah E. Appel, John E. Byers, Marshall D. Crew, Dwayne T. Friesen, Bruno C. Hancock, Stephen J. Schadtle
  • Patent number: 9180104
    Abstract: A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay. The modified release may be provided by (a) a high melt temperature, water-insoluble wax or waxy substance, (b) a low viscosity hydrophilic polymer such a hydroxypropyl methylcellulose, (c) a reverse enteric coating, or combinations thereof. The benzonatate may be in an adsorbate with a silico or silicate or in a complex with a weak acidic ion exchange resin complex.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: November 10, 2015
    Assignee: Tris Pharma, Inc.
    Inventors: Andrea Nelson, Quin-Zene Chen, Harsh Mehta, Yu-Hsing Tu
  • Patent number: 9180147
    Abstract: Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: November 10, 2015
    Assignee: Seres Therapeutics, Inc.
    Inventors: Gregory McKenzie, Mary-Jane Lombardo McKenzie, David N. Cook, Marin Vulic, Geoffrey von Maltzahn, Brian Goodman, John Grant Aunins, Matthew R. Henn, David Arthur Berry, Jonathan Winkler
  • Patent number: 9180124
    Abstract: Disclosed is nicotine containing solid oral transmucosal dosage forms containing a therapeutically effective amount of nicotine polacrilex, citric acid monohydrate, sucrose and liquid glucose. The dosage form is preferably in the form of lozenge.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: November 10, 2015
    Assignee: J. B. Chemicals and Pharmaceuticals Limited
    Inventors: Bharat Pravinchandra Mehta, Rajen Dhirubhai Shah, Manoj Kantilal Patel, Parmeshwar B. Bang
  • Patent number: 9180101
    Abstract: Disclosed is a pharmaceutical composition simultaneously having a rapid acting property and a long-acting property, comprising a sustained-release part coated with a water-insoluble polymer on the surface, comprising a first active pharmaceutical ingredient, at least one release control base selected from the group consisting of water-insoluble polymer, and water-soluble viscous polymer, and a pharmaceutically acceptable carrier; and, an immediate release part comprising a second active pharmaceutical ingredient and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: November 10, 2015
    Assignee: YUNGJIN PHARM CO., LTD.
    Inventors: Dong-Joon Oh, Byoung-Ki Kim, Byung-Kwan Moon, Ji-Seok Yoo, Dae-Hee Shin, Byung-Hwan Ryoo
  • Patent number: 9173845
    Abstract: A controlled release pharmaceutical composition comprising Milnacipran or pharmaceutically acceptable salts thereof and hydrophobic release controlling agent. The composition releases 90% of the total amount of Milnacipran or pharmaceutically acceptable salts thereof between 8 to 20 hours when dissolution is carried out in 900 ml 0.1N HCl, USP apparatus Type I (Basket) at 100 rpm for 2 hrs, followed by 900 ml Phosphate buffer pH 6.8 USP apparatus Type I (Basket) at 100 rpm. A process of preparing a controlled release pharmaceutical composition comprises: a) preparing a first layer comprising i) melting hydrophobic release controlling agent and Milnacipran or pharmaceutically acceptable salts thereof in it ii) cooling followed by sieving the melted mass to obtain granules and iii) lubricating the granules; and b) preparing a second layer comprising granules which comprises hydrophobic release controlling agent and optionally Milnacipran or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: November 3, 2015
    Assignee: LUPIN LIMITED
    Inventors: Shirish Kumar Kulkarni, Rajesh Kulkani, Pandharinath Jadhav, Ashish Tiwari
  • Patent number: 9168308
    Abstract: Disclosed is a nutritional supplement composition including effective amounts of Coenzyme Q10, fish oil, vitamin D and a pharmaceutically acceptable excipient. Described is a method of promoting nutritional health comprising administering a nutritional supplement composition including Coenzyme Q10, fish oil, vitamin D and a pharmaceutically acceptable excipient to a subject. The nutritional supplement composition may further include flax seed oil, borage oil, evening primrose oil, vitamin E, resveratrol, vitamin B6, vitamin B12, folic acid, piperine and combinations. In some embodiments, administering Administering the nutritional supplement may ameliorate nutrient depletion, or promote cardiovascular health, liver health, or both. The nutritional supplement may be used to promote nutritional health taking a cholesterol lowering drug. The nutritional supplement may be used to ameliorate nutrient depletion taking a cholesterol lowering drug. The cholesterol lowering drug may be a statin.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: October 27, 2015
    Inventor: Paul Joseph Faerstein
  • Patent number: 9169257
    Abstract: The present invention relates to novel Forms A, B, C, D, E, F and G of crystalline 9-[2-[phosphonomethoxy]ethyl]adenine bis-pivaloyloxymethyl ester, i.e., adefovir dipivoxil, and processes for preparing them. According to the present invention, said novel crystal forms having a high purity can be obtained by a simple method and in a high yield.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: October 27, 2015
    Assignees: Daewoong Pharmaceutical Co., Ltd., Daewoong Bio Inc.
    Inventors: Soo Jin Choi, Byung Goo Lee, Seong Soo Oh, Yong Tae Kim, Kwang Joo Kim, Hye Jin Kim
  • Patent number: 9161909
    Abstract: Compositions for the treatment of xerostomia, and methods of making and using thereof are disclosed herein. The compositions are typically in the form of a film or tablet, such as a double layer sticker tablet. The compositions adhere to a buccal surface or mucosal surface in the oral cavity for at least 15 minutes, preferably for at least 30 minutes. The compositions themselves are able to increase the levels of saliva in the mouth without the need for active agents, such sialogogic agents. The compositions optionally contain a non-lipid lubricant, a flavoring agent, and/or a buffering agent. The composition is generally effective at treating or ameliorating the effects of xerostomia for a time period ranging from at least 30 minutes up to eight hours following administration to the buccal or oral mucosa.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: October 20, 2015
    Assignee: Axiomedic Ltd.
    Inventors: Abraham J. Domb, Benny Brama, Boaz Mizrahi
  • Patent number: 9151990
    Abstract: An LCD device adapted to improve a residual image matter is disclosed. The LCD device includes an alignment layer aligning the liquid crystal. The alignment layer is formed of an optically aligned composition inclusive of an aromatic compound. Also, the alignment layer undergoes a crosslinking process. In accordance therewith, the thermalization of the alignment layer is improved. As a result, the residual image problem of the LCD device can be solved.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: October 6, 2015
    Assignee: LG Display Co., Ltd.
    Inventor: Dong Cheon Shin
  • Patent number: 9132136
    Abstract: The present invention relates to a pharmaceutical combination for the treatment of schizophrenia and acute manic episodes associated with bipolar disorders, which comprises a compound which is active on a trace amine-associated receptor 1 (TAAR1 agonist) and an antipsychotic drug. This combination can reduce metabolic side effects which appear if using an antipsychotic drug alone.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: September 15, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Marius Hoener, Susanne Raab, Celine Risterucci, Sabine Sewing
  • Patent number: 9125868
    Abstract: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: September 8, 2015
    Assignee: OREXIGEN THERAPEUTICS, INC.
    Inventors: Anthony A. McKinney, Gary Tollefson, Eckard Weber, Rick Soltero
  • Patent number: 9125809
    Abstract: There is disclosed a technique for making a jelly formulation comprising pectin slide out of a container easily (improving the slidability of the jelly formulation) when taking the formulation out of the container to prevent the formulation from remaining in the container. The jelly formulation of the present invention comprises a drug, pectin, divalent metal ions, and polyoxyethylene polyoxypropylene glycol.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: September 8, 2015
    Assignee: NICHI-IKO PHARMACEUTICAL CO., LTD.
    Inventors: Yoichiro Goto, Kurato Takanashi, Teruo Maruta, Masatake Dairaku
  • Patent number: 9119820
    Abstract: The present invention relates to a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient at a high content and a production method thereof. That is, the present invention provides a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient in not less than 25% of the total weight, having a disintegration time of within 40 seconds and an absolute hardness of 1.8 N/mm2 or more, which is obtained by granulating a powder containing an active ingredient with a binding solution containing mannitol and corn-derived pregelatinized starch, mixing the resulting granules with at least one kind of a disintegrant selected from cornstarch, hydroxypropylstarch, carmellose and crospovidone, and compression molding the mixture.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: September 1, 2015
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Toru Fukushima, Takashi Shimizu, Teruko Yoshida
  • Patent number: 9119794
    Abstract: The present invention pertains to a process for the preparation of a fast-disintegrating tablet (30) containing a medicinal substance, comprising the steps of providing a fluid formulation comprising the medicinal substance, providing a solid element (100) having formed therein at least one cavity, (101) cooling the solid element (100) to a temperature below a freezing temperature of the formulation, filling the cavity with the fluid formulation, solidifying the formulation while present in the cavity (101) to form a solid pellet comprising the medicinal substance without actively shaping the entire surface of the pellet, taking the pellet out of the cavity and drying the pellet in a vacuum to obtain the tablet. The invention also pertains to a system for performing such a process and a package containing the resulting tablet.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: September 1, 2015
    Assignee: Intervet International B.V.
    Inventors: Hans Almer Middelbeek, Jozefus A. C. Smit
  • Patent number: 9119790
    Abstract: The invention concerns a co-processed additive for a solid-dose pharmaceutical composition, the additive comprising from about 50% to 99.5% by weight of at least one pharmaceutical compression aid and from about 0.5% to 50% by weight of at least one pharmaceutical lubricant, the melting point of said compression aid(s) being higher than the melting point of said lubricant(s). The co-processed additive may be in the form of a physically bound composite whereby the lubricant is associated with the surface of the compression aid particles.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: September 1, 2015
    Assignee: ZENBURY INTERNATIONAL LIMITED
    Inventors: Michael Crowley, Amanda Gage, Jack Maegli, Timothy O'Reilly
  • Patent number: 9107921
    Abstract: A pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The tablet is a matrix tablet and a single-dose administration of one or more tablets to a subject under fasted conditions provides a mean Cm˜ for each of the first active agent and the second active agent that is 70% to 135% of a respective mean Cm˜ provided by administering an immediate release oral dosage form to a subject under fasted conditions every 4 to 6 hours over a 12 hour time period, wherein cumulative dosage amounts administered over the 12 hour time period of each active agent is equivalent to the respective amount of each active agent in the pharmaceutical tablet.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: August 18, 2015
    Assignee: Spriaso LLC
    Inventors: Chandrashekar Giliyar, Satish Kumar Nachaegari, Chidambaram Machiappan, Mahesh V. Patel, Srinivasan Venkateshwaran
  • Patent number: 9107836
    Abstract: The present invention relates to a hygroscopic matrix based formulation, a process for the preparation thereof and its use in the treatment of diseases.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: August 18, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Michaela Krabichler, Bernard Meyer, Carsten Winzenburg
  • Patent number: 9089488
    Abstract: The invention relates to an improved process for preparing a new medicament formulation of the active substance dabigatran etexilate of formula I in the form of the methanesulphonic acid salt thereof, and this new medicament formulation as such.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: July 28, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Guido Bernhard Edmund Radtke
  • Patent number: 9078824
    Abstract: The present invention comprises a method of achieving ingredient stabilization in a composition comprising the steps of: combining a pregelatinized starch with at least one sensitive ingredient; adsorbing said sensitive ingredient onto the pregelatinized starch; and wherein said sensitive ingredient is evenly distributed throughout said pregelatinized starch.
    Type: Grant
    Filed: September 23, 2008
    Date of Patent: July 14, 2015
    Assignee: The Procter & Gamble Company
    Inventors: Paul Alfred Cimiluca, Sonsoles Arnal, Jorge Zambrano
  • Patent number: 9078947
    Abstract: A porous absorbent structure is disclosed which includes absorbent particles and a superabsorbent polymer material having less than about 1000 parts per million residual monoethylenically unsaturated monomer, the superabsorbent polymer material substantially coating the absorbent particles and connecting the particles into a porous network to form the porous absorbent structure.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 14, 2015
    Assignee: KIMBERLY-CLARK WORLDWIDE, INC.
    Inventors: John Gavin MacDonald, Peter B. Dulcamara, Jr., Dave A. Soerens, Thomas J. Falk
  • Patent number: 9072784
    Abstract: The invention relates to a method for stabilizing solid pharmaceutical administration forms which comprises at least one species of microorganism, and to a pack comprising packaging and a solid pharmaceutical administration form which comprises at least one species of microorganism.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: July 7, 2015
    Assignee: Merck Patent GmbH
    Inventors: Markus Rudolph, Stefan Henke, Iris Manneck, Holger Peitz, Andrea Christ
  • Patent number: 9050356
    Abstract: The present invention relates to compositions comprising chitosan, in the form of drugs or food supplements, suitable for comprehensive therapeutic treatment or comprehensive prevention of the metabolic syndrome. Also described is their preparation. More generally, the invention concerns the use of chitosan for comprehensive therapeutic treatment or comprehensive prevention of the metabolic syndrome.
    Type: Grant
    Filed: March 2, 2007
    Date of Patent: June 9, 2015
    Assignee: Cor. Con. International S.R.L.
    Inventor: Umberto Cornelli
  • Patent number: 9045438
    Abstract: Pharmaceutical compositions of the active substances glimepiride with metformin or its salts such as hydrochloride, succinate, furmarate, etc. are useful to control blood glucose in patients with type 2 diabetes. To prove the effectiveness of the combination, clinical studies were conducted that demonstrated the existence of not only an additive effect, but also a synergistic effect of the two drugs compared with monotherapy using only one of the drugs used in combination. In consequence, the combination may be used as an effective and safe therapy to control blood glucose in patients with type 2 diabetes, using different proportions of the active substances in combinations suitable for the needs of different patients.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: June 2, 2015
    Assignee: Silanes S.A. de C.V.
    Inventor: Jose Manuel Francisco Lara Ochoa
  • Patent number: 9044478
    Abstract: Use of 1,4-bis(3-aminoalkyl)piperazine derivatives as defined in formula I or II for the manufacture of a pharmaceutical composition intended for the treatment of neurodegenerative diseases, related neurodegenerative diseases, developmental diseases or cancer. The instant invention is also directed to some specific 1,4-bis(3-aminoalkyl)piperazine derivatives and pharmaceutical composition including them.
    Type: Grant
    Filed: November 8, 2005
    Date of Patent: June 2, 2015
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE DU DROIT ET DE LA SANTA-LILLE II
    Inventors: Nicolas Sergeant, Andre Delacourte, Patricia Melnyk, Luc Buee
  • Publication number: 20150147392
    Abstract: A method of arresting blood flow from a bleeding wound including the steps of (1) providing a solid hemostatic tablet preferably including potassium ferrate and a cation ion exchange resin pressure formed into a tablet for delivery onto a bleeding wound, the tablet defining a proximal portion and a distal portion, (2) applying the proximal portion against the bleeding wound to improve the rate of adhesion to a bleeding wound surface, and then (3) applying pressure against the tablet over the wound site. After the seal is formed from the interaction of blood or exudates with the proximal portion of the tablet, the distal portion of the tablet delaminates from the proximal portion to form a reservoir to stop further bleeding and to provide antimicrobial protection and healing. The tablet may be applied to any surface orientation and take any shape and thickness possible.
    Type: Application
    Filed: January 27, 2015
    Publication date: May 28, 2015
    Inventors: John Hen, Talmadge Kelly Keene, Mark Travi
  • Patent number: 9040084
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: May 26, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Publication number: 20150140092
    Abstract: The invention relates generally to methods of making formulations for delivering biological agents to a patient. In one aspect, proliposomal drug-delivery systems for medicaments are provided. In another aspect, coated proliposomal formulations for poorly water soluble drugs, and methods for making the same, are provided. Certain embodiments of the present invention provide enhanced stability and bioavailability for pharmaceutical formulations.
    Type: Application
    Filed: November 17, 2014
    Publication date: May 21, 2015
    Inventor: Guru V. BETAGERI
  • Publication number: 20150140093
    Abstract: Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 ?m to about 20 ?m.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 21, 2015
    Inventors: Cory J. Berkland, Lianjun Shi, Nashwa El Gendy, Carl Plumley, Mark Bailey
  • Patent number: 9034410
    Abstract: Disclosed are novel processing methods for green coffee beans that result in novel green coffee bean products, including products that incorporate whole green coffee beans. Methods include selecting whole coffee beans in their fresh green unroasted state with naturally-occurring levels of phytonutrients, sterilizing and drying them, applying iterative grinding processes and stabilization techniques, all while avoiding high temperatures. Whole green coffee bean products created and defined by these methods have unexpectedly been found to increase focus and concentration in users, and are believed useful in the treatment of attention and concentration deficits and related disorders, such as attention deficit (AD), attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and various related and/or comorbid disorders.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: May 19, 2015
    Inventors: Thomas J. Vella, Samuel A. Amen
  • Patent number: 9034377
    Abstract: The present invention relates to a plurality of dosage forms comprising a first dosage form and second dosage form each comprising a therapeutic agent, such as an opioid; wherein the dosage strength of the second dosage form is greater than that of the first dosage form; and wherein the steady state Cave and the steady state AUC of the first and second dosage forms are dose proportional and the single dose Cmax of the second dosage form is less than the minimum level for dose proportionality with respect to the first dosage form. The present invention also relates to methods of administering such dosage forms to a patient, as well as to kits comprising such dosage forms and instructions for administration of the dosage forms to a patient. The inventors believe that the dosage forms and methods of the present invention will lead to improved safety and patient acceptance.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: May 19, 2015
    Assignee: Purdue Pharma, L.P.
    Inventors: Curtis Wright, Robert Colucci, Ahmed El-Tahtawy
  • Patent number: 9028867
    Abstract: The present invention provides a tablet comprising a plurality of drug-containing parts and at least one connecting part adhered to the drug-containing parts, and having a scored line capable of dividing the whole tablet on the connecting part; particularly, a coated tablet in which a connecting part and a coating layer have the same or different drug release controlling functions; a tablet having an insoluble coating on a drug-containing part having a scored line, wherein the drug-containing part has a structure or composition such that the drug is substantially released after the tablet is divided along the scored line and then ingested; and a tablet comprising a plurality of drug-containing parts and at least one connecting part adhered to the drug-containing parts, wherein at least two drug-containing parts have different compositions.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: May 12, 2015
    Assignee: Teijin Pharma Limited
    Inventors: Masahiko Narasaki, Tomoya Akutagawa, Reiko Oku
  • Patent number: 9028876
    Abstract: Rate-controlled particles, comprising compounds of the formula as a solid dispersion.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: May 12, 2015
    Assignee: Janssen R&D Ireland
    Inventors: Thomas Hantke, Bettina Rehbock, Jörg Rosenberg, Jörg Breitenbach
  • Patent number: 9028868
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 3 to 8 hours, followed by an ascending release rate.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: May 12, 2015
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 9029355
    Abstract: In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: May 12, 2015
    Assignee: Marinus Pharmaceuticals
    Inventors: Kenneth Shaw, Mingbao Zhang